Zhenwei Su
Impact in
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery
-
- Immunotherapy and Immune Responses
- Immune cells in cancer
Papers in
-
- Nanoplatforms for cancer theranostics 8
- Graphene and Nanomaterials Applications 1
-
- Nanoparticle-Based Drug Delivery 7
- Co-authors
- Xintao Shuai (7 shared papers)Zecong Xiao (3 shared papers)Jinsheng Huang (3 shared papers)Yong Wang (5 shared papers)Shisong Han (3 shared papers)Xingyu Jiang (3 shared papers)Liteng Lin (1 shared paper)Yongcheng An (2 shared papers)
- Journals
- Advanced Science (1 paper)Chemical Communications (1 paper)Acta Pharmaceutica Sinica B (1 paper)Drug Resistance Updates (1 paper)Small (1 paper)
- Partner nations
- ChinaDenmarkUnited States
In The Last Decade
Zhenwei Su
12 papers receiving 607 citations
Peers
Comparison fields: 5 of 68
- Biomaterials 185
- Immunology 162
- Biomedical Engineering 322
- Oncology 140
- Molecular Biology 210
Countries citing papers authored by Zhenwei Su
This map shows the geographic impact of Zhenwei Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenwei Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenwei Su more than expected).
Fields of papers citing papers by Zhenwei Su
This network shows the impact of papers produced by Zhenwei Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenwei Su. The network helps show where Zhenwei Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Zhenwei Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 144 | |
| 2 | 2020 | 133 | |
| 3 | 2020 | 103 | |
| 4 | 2021 | 51 | |
| 5 | 2023 | 33 | |
| 6 | 2019 | 30 | |
| 7 | 2015 | 29 | |
| 8 | 2023 | 27 | |
| 9 | 2017 | 27 | |
| 10 | 2024 | 14 | |
| 11 | 2020 | 12 | |
| 12 | 2025 | 5 | |
| 13 | 2025 | 0 |
About Zhenwei Su
Zhenwei Su is a scholar working on Biomedical Engineering, Biomaterials, Oncology, Immunology and Molecular Biology, having authored 13 papers that have together received 608 indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (8 papers), Nanoparticle-Based Drug Delivery (7 papers), Immunotherapy and Immune Responses (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), RNA Interference and Gene Delivery (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (1 paper), Graphene and Nanomaterials Applications (1 paper) and Peptidase Inhibition and Analysis (1 paper). The work is most often cited by research in Biomaterials (185 citations), Immunology (162 citations), Biomedical Engineering (322 citations), Oncology (140 citations) and Molecular Biology (210 citations). Zhenwei Su has collaborated with scholars based in China, Denmark and United States. Frequent co-authors include Xintao Shuai, Zecong Xiao, Jinsheng Huang, Yong Wang, Shisong Han, Xingyu Jiang, Liteng Lin, Yongcheng An, Chang Zou and Shaowei Dong. Their work appears in journals such as Advanced Science, Chemical Communications, Acta Pharmaceutica Sinica B, Drug Resistance Updates and Small.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.